Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

Haematologica

Volumn 100, Issue 1, 2015, Pages 17-22

  Niemeyer, Charlotte M ^a   Loh, Mignon L ^b   Cseh, Annamaria ^a   Cooper, Todd ^c   Dvorak, Christopher C ^d   Chan, Rebecca ^e   Xicoy, Blanca ^f   Germing, Ulrich ^g   Kojima, Seiji ^h   Manabe, Atsushi ⁱ   Dworzak, Michael ^j   De Moerloose, Barbara ^k   Starý, Jan ^l   Smith, Owen P ^m   Masetti, Riccardo ⁿ   Catala, Albert ^o   Bergstraesser, Eva ^p   Ussowicz, Marek ^q   Fabri, Oskana ^r   Baruchel, André ^s   Cavé, Hélène ^s   Zwaan, Michel ^t   Locatelli, Franco ^u   Hasle, Henrik ^v   Van Den Heuvel Eibrink, Marry M ^t   Flotho, Christian ^a   Yoshimi, Ayami ^a   more..

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

^l UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^m OUR LADY S CHILDREN S HOSPITAL   (Ireland)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

^o HOSPITAL SANT JOAN DE DÉU   (Spain)

^p UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^q WROCLAW MEDICAL UNIVERSITY   (Poland)

^r Faculty of Natural Sciences   (Slovakia)

^s HÔPITAL ROBERT DEBRÉ   (France)

^t SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^u UNIVERSITY OF PAVIA   (Italy)

^v AARHUS UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ARTICLE; CHIMERA; CYTOGENETICS; ECHOGRAPHY; ERYTHROID PRECURSOR CELL; GENE MUTATION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; KARYOTYPE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MOLECULAR GENETICS; MYELOID PROGENITOR CELL; ONCOGENE N RAS; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REMISSION; SPLEEN SIZE; TREATMENT RESPONSE; CHILD; CLINICAL TRIAL (TOPIC); LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MORTALITY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PREVENTION AND CONTROL; PROGNOSIS; STANDARDS; SURVIVAL RATE; TUMOR RECURRENCE;

CHILD; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SURVIVAL RATE;

EID: 84920147335     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.109892     Document Type: Article

References (33)

1. Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol. 2008;140 (6):610-24.
2. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol. 2011; 152(6):677-87.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American- British Cooperative Leukaemia Group. Br J Haematol. 1994; 87(4):746-54.
4. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu RA, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89(10):3534-43.
5. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003; 34(2):148-50.
6. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergsträsser E, Emanuel PD, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood. 2005;106(6):2183-5.
7. Miyauchi J, Asada M, Sasaki M, Tsunematsu Y, Kojima S, Mizutani S. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83(8):2248-54.
8. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type1. Blood. 1998;92(1):267-72.
9. Flotho C, Valcamonica S, Mach-Pascual S, Schmahl G, Corral L, Ritterbach J, et al. Ras mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13(1):32-7.
10. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009; 114(9):1859-63.
11. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010;42(9):794-800.
12. de Vries AC, Zwaan CM, van den Heuvel-Eibrink MM. Molecular basis of juvenile myelomonocytic leukemia. Haematologica. 2010; 95(2):179-82.
13. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105(1):410-9.
14. Yabe M, Sako M, Yabe H, Osugi Y, Kurosawa H, Nara T, et al. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. Pediatr Transplant. 2008; 12(8):862-7.
15. Locatelli F, Crotta A, Ruggeri A, Eapen M, Wagner JE, Macmillan ML, et al. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood. 2013;122(12):2135-41.
16. Castleberry RP, Emanuel PD, Zuckerman KS, Cohn S, Strauss L, Byrd RL, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med. 1994;331(25):1680-4.
17. ®) in untreated juvenile myelomonocytic leukemia (JMML): A Children's Oncology Group study [abstract]. Blood. 2005; 106:727a.
18. Shimada H, Shima H, Shimasaki N, Yoshihara H, Mori T, Takahashi T. Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation. Ann Oncol. 2005;16(8):1400.
19. Furlan I, Batz C, Flotho C, Mohr B, Lübbert M, Suttorp M, et al. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009;113(12):2867-8.
20. Cseh A, Niemeyer CM, Catalá A, Dworzak M, Hasle H, van den Heuvel-Eibrink MM, et al. Therapy with azacitidine in pediatric MDS and JMML A retrospective survey of the EWOG-MDS study. Haematologica. 2012;97:S3.
21. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, et al. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med. 2011;3:76ra27.
22. Chang T, Krisman K, Theobald EH; Xu J, Akutagawa J, Lauchle JO, et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013;123(1):335-9.
23. Goodwin CB, Li XJ, Mali RS, Chan G, Kang M, Liu Z et al. PI3K p110delta uniquely promotes gain-of-function Shp2-induced GMCSF hypersensitivity in a model of JMML. Blood. 2014;23(18):2838-42.
24. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671-4.
25. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.
26. Bergstraesser E, Hasle H, Rogge T, Fischer A, Zimmermann M, Noellke P, et al. Nonhematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer. 2007;49(5):629-33.
27. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009;33(3):355-62.
28. Ades L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013;37(6):609-13.
29. Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007;109(4):713-7.
30. Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahé B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood. 1996;88(7):2480-7.
31. Lamb PM, Lund A, Kanagasabay RR, Martin A, Webb JA, Reznek RH, et al. Spleen size: how well do linear ultrasound measurements correlate with three-dimensional CT volume assessments? Br J Radiol. 2002; 75(895):573-7.
32. Sakaguchi H, Okuno Y, Muramatsu, Yoshida K, Shiraishi Y, Takahashi M, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013;45(8):937-41.
33. Yoshimi A, Niemeyer CM, Bohmer V, Duffner U, Strahm B, Kreyenberg H, et al. Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. Br J Haematol. 2005;129(4):542-9.